ZygoFix has developed a proprietary approach to spinal stabilization and spinal fusion. The company's zLOCK system utilizes our spine’s natural anatomy for spinal stability.
The system offers all around benefits to the $2.2 billion worldwide addressable spine market.
ZygoFix is a privately held company, founded in 2017 by Professor Yizhar Floman and Uri Arnin.
Improve spinal fusion clinical outcomes in the most minimally invasive fashion by providing solutions aligned with our natural anatomy.
15 years experience in the medical device industry as an engineer, product manager, and consultant; deep understanding of medical device development and lifecycle; MBA, Tel Aviv University, B.Sc., mechanical engineering, Ben-Gurion University of the Negev
Serial entrepreneur in the field of spinal implants; 30 years’ experience in medical device industry; 29 issued patents and 43 pending (all in spine); former CTO, Impliant (world’s first facet replacement device); CTO, Spine 21 (world’s first remote-controlled spinal implant); founder and CTO, ApiFix (Aquired by Orthopediatrics 04.2020).
Prof. Yizhar Floman
Co-founder, Medical Director
Chairman and Director, Israel Spine Center, Assuta Hospital, Tel Aviv; former Chief of Spine Surgery, Hadassah Hebrew University Medical Center, Jerusalem; President, Israel Orthopedic Association; member of numerous organizations, including Scoliosis Research Society, International Society for the Study of the Lumbar Spine, Spine Society of Europe, and the North American Spine Society.
Board of Directors
ZygoFix's board consists of experienced executives with a track record in growing innovative technologies to successful companies.
Nick is seasoned Life Science leader combining his clinical, technical, and business experience to anticipate market trends, identify transformational opportunities, and accelerate their path to clinical and commercial success.
Previously, Nick led Global External Innovation for Johnson & Johnson’s Orthopedic Franchise. Nick has created multiple new commercial ventures while at DePuy Synthes and Arthrex (Digital Surgery & Robotics, Ambulatory Surgery Centers, Sports Medicine, Extremities). He has also developed and restructured startups for successful exits (SBI to Stryker, Scient’X to Alphatec).
Nick is a graduate of the University of Pittsburgh and received his Doctor of Podiatric Medicine degree from the Pennsylvania School of Podiatric Medicine. His surgical residency was at the University of Medicine and Dentistry of New Jersey. He completed an Orthopedic Trauma Fellowship in Germany and went on to clinical practice for ten years, prior to joining industry in 2003.
Ofir Hazut has over 12 years of experience and knowledge in life science start-ups and companies. He served as Director of Business Development and CEO in medical devices and agrotech companies. Prior to joining Trendlines, Ofir held the position of Director of Business Development at Evogene and CEO of MEway Pharma, a medical device company funded by Sanara Ventures (a medical incubator backed by Phillips and TEVA). Ofir Hazut advised VCs in investment strategy, deal flow and due diligence processes.
Ofir received his B.Sc in Neuroscience and MBA from Bar-Ilan University and M.Sc in Bio-Psychology from Tel-Aviv University.
Barak Singer has over 15 years of experience in management, business development, investment banking, and venture capital.
Among others, Barak served as VP Business Development at Can-Fite BioPharma (NYSE: CANF) and CEO of its subsidiary Ophthalix, VP Business Development at Xenia Venture Capital, and was a Co-Founder and CEO at Or Capital Healthcare Partners.
Barak currently serves as the CEO of Trendlines Israel Incubator.
Over 20 years experience in the US medical device industry. Successful commercialization and revenue generation at Zimmer Spine, Centinel Spine, Wenzel Spine and most recently Prosidyan which exclusive rights were acquired by DePuy Synthes in June, 2018. Mr. Luedke is currently, President & CEO of Spineway USA, Inc., a French based publicly traded company that treats severe spinal column pathologies.